KLC2 and hematopoietic and lymphoid system neoplasm: Recent studies [28–30] have reported the acquisition of additional genetic alterations during blastic transformation; among them, KLC2 mutations have not been reported in the context of hematological neoplasms, which we sought to address for the biological role of KLC2-WT, KLC2-R312W, and KLC2-L523I mutations in CML-to-CML-BP transformation.